Clinical trials: Physical Activity
Advanced Solid Tumor
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid…
- Trial name
- NCT07414836
- Testing
- BG-C0979, Tislelizumab
- Where
- 18 sites in United States, Australia and 2 more
- Volunteers
- 84 people
- Sponsor
- BeOne Medicines
Neoplasms
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin.
- Trial name
- NCT00421811
- Testing
- ADH-1, melphalan
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Adherex Technologies, Inc.
Pain, Knee Osteoarthritis
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to…
- Trial name
- NCT00486811
- Testing
- Tapentadol ER (100 to 250 mg twice daily), Oxycodone CR (20 to 50 mg twice daily)
- Where
- 100 sites in Austria, Croatia and 11 more
- Volunteers
- 990 people
- Sponsor
- Grünenthal GmbH
Tinea
Efficacy Study to Evaluate the Effect of Nitric Oxide on the Treatment of Tinea Pedis (Athlete's Foot)
The purpose of this study is to determine the fungicidal efficacy of nitric oxide and it's effect on the clinical signs and symptoms associated with Tinea Pedis
- Trial name
- NCT00771342
- Testing
- Nitric Oxide, Nitrogen
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Nitric BioTherapeutics, Inc
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Advanced Solid Malignancies
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
The objectives of this Phase I study are to determine the maximum tolerable dose (MTD) and to evaluate pharmacokinetics (PK), safety/ tolerability and preliminary efficacy of OB318 in patients with advanced solid malignancies.
- Trial name
- NCT02347228
- Testing
- OB318 capsule
- Where
- 2 sites in Taiwan
- Volunteers
- 21 people
- Sponsor
- Oneness Biotech Co., Ltd.
Attention Deficit Hyperactivity Disorder
Study to Evaluate the Efficacy of Modafinil Treatment in Patients With Attention Deficit Hyperactivity Disorder (ADHD) Who Are Responders to Modafinil Treatment
The purpose of this study is to evaluate the continued efficacy of modafinil treatment, compared to placebo treatment, in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who are responders to…
- Trial name
- NCT00343811
- Testing
- Modafinil
- Where
- 23 sites in United States
- Volunteers
- 120 people
- Sponsor
- Cephalon
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment.
- Trial name
- NCT07766499
- Testing
- THB335 Lower Dose, THB335 Higher Dose
- Volunteers
- 81 people
- Sponsor
- Calixis Inc.
Neoplasms
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
- Trial name
- NCT05993299
- Testing
- Letetresgene autoleucel, Cyclophosphamide, Fludarabine
- Where
- 38 sites in United States, Canada and 5 more
- Volunteers
- 7 people
- Sponsor
- USWM, LLC (dba US WorldMeds)
Overweight, Obesity
Food, Activity and Behavior Trial
This study will provide data on the response over 24 months to two commercial weight loss programs (center-based and telephone-based) compared to control conditions.
- Trial name
- FAB (NCT00640900)
- Testing
- Usual care, Commercial weight loss program
- Where
- United States
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Jenny Craig, Inc.
Breast Cancer, Advanced Solid Tumor
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in…
- Trial name
- NCT07222267
- Testing
- BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist
- Where
- 32 sites in United States, Australia and 4 more
- Volunteers
- 86 people
- Sponsor
- BeOne Medicines
Newly Diagnosed Glioblastoma
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
This is a phase 1/2, randomized, placebo-controlled study to evaluate safety, tolerability, anti-tumor activity and impact on absolute lymphocyte count of GX-I7 plus adjuvant temozolomide combination regimen in patients with…
- Trial name
- NCT04065087
- Testing
- GX-I7
- Where
- South Korea
- Sponsor
- Genexine, Inc.
Treatment, Osteoarthritis
Evaluate Safety & Efficacy of Condroflex in Subjects With OA
Primary Objective: To compare, after 12 weeks of double-blind treatment, the evolution of the improvement of pain (at rest and during / after exercise) in the questionnaire WOMAC (Western Ontario and McMaster Universities…
- Conditions
- Treatment, Osteoarthritis, Elderly
- Trial name
- ZD20108 (NCT00838487)
- Testing
- condroflex and exercise, sugar pill and exercise
- Where
- Brazil
- Volunteers
- 240 people
- Sponsor
- Zodiac Produtos Farmaceuticos S.A.
Advanced Solid Tumours
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics(PK) and anti-tumour activity of adavosertib in Japanese patients with advanced solid tumours.
- Trial name
- NCT04462952
- Testing
- Adavosertib (AZD1775)
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
COPD
Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study assessed the effect of once-daily indacaterol and glycopyrronium bromide (QVA149) on exercise endurance in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- BRIGHT (NCT01294787)
- Testing
- indacaterol and glycopyrronium bromide (QVA149), tiotropium
- Where
- 13 sites in Germany, Spain
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
HIV-1-infection
Dose Escalation Safety Study of TMB-365 in HIV-1 Infected Participants
This study will evaluate the safety and behavior in the body of the experimental drug TMB-365 in people with HIV-1 infection. This will be the first test of TMB-365 in humans.
- Trial name
- NCT04027387
- Testing
- TMB-365
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- TaiMed Biologics Inc.
Liposarcoma, Prostate Cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
- Conditions
- Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- CDK4i (NCT04557449)
- Testing
- PF-07220060, Letrozole, Fulvestrant
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 430 people
- Sponsor
- Pfizer
Mood, Depression Disorders
Technology Exposure and Child Health: Wellness Impact and Social Effects: An Observational Product Registry Study
The goal of this study is to understand how children's mobile device usage (smartphones or tablets), including social media use and online games, are related to their mental wellness and mental health, as well as some aspects of…
- Conditions
- Mood, Depression Disorders, Anxiety Disorders, Sleep
- Trial name
- TECHWISE (NCT06664944)
- Where
- United States
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- Aura
Metastatic Solid Tumors, Locally Advanced Solid Tumors
This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.
The purpose of this study is to establish the maximum tolerated dose (MTD) of OBI-888 as monotherapy. And to characterize the safety and preliminary clinical activity profile of the MTD dose of OBI-888 administered as monotherapy…
- Trial name
- NCT03573544
- Testing
- OBI-888, Globo H IHC Assay
- Where
- 9 sites in United States, Taiwan
- Volunteers
- 54 people
- Sponsor
- OBI Pharma, Inc
Alzheimer's Disease
Safety/Tolerability, Immunological and Clinical Activity of a Boost Immunization With AFFITOPE AD02
This is a phase IB follow-up study to assess a boost immunization with AFFITOPE AD02 with regard to safety/tolerability, immunological and clinical activity in Alzheimer patients who have received the vaccine within the clinical…
- Trial name
- NCT01093664
- Testing
- AFFITOPE AD02
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Affiris AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.